Cargando…

Final Report on Clinical Outcomes and Tumor Recurrence Patterns of a Pilot Study Assessing Efficacy of Belinostat (PXD-101) with Chemoradiation for Newly Diagnosed Glioblastoma

Glioblastoma (GBM) is highly aggressive and has a poor prognosis. Belinostat is a histone deacetylase inhibitor with blood–brain barrier permeability, anti-GBM activity, and the potential to enhance chemoradiation. The purpose of this clinical trial was to assess the efficacy of combining belinostat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Karen, Ramesh, Karthik, Huang, Vicki, Gurbani, Saumya S., Cordova, James Scott, Schreibmann, Eduard, Weinberg, Brent D., Sengupta, Soma, Voloschin, Alfredo D., Holdhoff, Matthias, Barker, Peter B., Kleinberg, Lawrence R., Olson, Jeffrey J., Shu, Hui-Kuo G., Shim, Hyunsuk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8938806/ https://www.ncbi.nlm.nih.gov/pubmed/35314634 http://dx.doi.org/10.3390/tomography8020057

Ejemplares similares

Mutant Isocitrate Dehydrogenase 1 Expression Enhances Response of Gliomas to the Histone Deacetylase Inhibitor Belinostat
por: Chang, Chi-Ming, et al.
Publicado: (2023)

The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo
por: Buckley, Michael T, et al.
Publicado: (2007)

A Phase I/II Clinical Trial of Belinostat (PXD101) in Combination with Doxorubicin in Patients with Soft Tissue Sarcomas
por: Vitfell-Rasmussen, Joanna, et al.
Publicado: (2016)

A multi-institutional pilot clinical trial of spectroscopic MRI-guided radiation dose escalation for newly diagnosed glioblastoma
por: Ramesh, Karthik, et al.
Publicado: (2022)

Assessing Treatment Response of Glioblastoma to an HDAC Inhibitor Using Whole-Brain Spectroscopic MRI
por: Gurbani, Saumya S., et al.
Publicado: (2019)

The Longitudinal Imaging Tracker (BrICS-LIT):A Cloud Platform for Monitoring Treatment Response in Glioblastoma Patients
por: Ramesh, Karthik, et al.
Publicado: (2020)

A Novel Approach to Determining Tumor Progression Using a Three-Site Pilot Clinical Trial of Spectroscopic MRI-Guided Radiation Dose Escalation in Glioblastoma
por: Ramesh, Karthik K., et al.
Publicado: (2023)

Remarkable response of a patient with secondary glioblastoma to a histone deacetylase inhibitor
por: Gurbani, Saumya S, et al.
Publicado: (2020)

Presentation of treatment effect in glioblastoma after dose-escalation radiation therapy
por: Cicka, Danielle, et al.
Publicado: (2019)

The Brain Imaging Collaboration Suite (BrICS): A Cloud Platform for Integrating Whole-Brain Spectroscopic MRI into the Radiation Therapy Planning Workflow
por: Gurbani, Saumya, et al.
Publicado: (2019)

Utility of a Histone Deacetylase Inhibitor (PXD101) for Thyroid Cancer Treatment
por: Lin, Shu-Fu, et al.
Publicado: (2013)

The role of erlotinib and the Optune device in a patient with an epidermal growth factor receptor viii amplified glioblastoma
por: Doyle, Sean P, et al.
Publicado: (2018)

A Systematic Pipeline for the Objective Comparison of Whole-Brain Spectroscopic MRI with Histology in Biopsy Specimens from Grade 3 Glioma
por: Cordova, J. Scott, et al.
Publicado: (2016)

Applying a Radiation Therapy Volume Analysis Pipeline to Determine the Utility of Spectroscopic MRI-Guided Adaptive Radiation Therapy for Glioblastoma
por: Trivedi, Anuradha G., et al.
Publicado: (2023)

Simulating the Effect of Spectroscopic MRI as a Metric for Radiation Therapy Planning in Patients with Glioblastoma
por: Cordova, J. Scott, et al.
Publicado: (2016)

Spectroscopic MRI-Based Biomarkers Predict Survival for Newly Diagnosed Glioblastoma in a Clinical Trial
por: Trivedi, Anuradha G., et al.
Publicado: (2023)

Repurposing Belinostat for Alleviation of Atopic Dermatitis
por: Quah, Shan, et al.
Publicado: (2021)

Planning by design (PxD)-based systematic methodologies
por: Butuner, Hakan
Publicado: (2017)

Belinostat for Relapsed or Refractory Peripheral T-Cell Lymphoma
por: Hood, Katelyn, et al.
Publicado: (2016)

Hematologic toxicity is rare in relapsed patients treated with belinostat: a systematic review of belinostat toxicity and safety in peripheral T-cell lymphomas
por: Allen, Pamela B, et al.
Publicado: (2018)

A Fully Automated Post-Surgical Brain Tumor Segmentation Model for Radiation Treatment Planning and Longitudinal Tracking
por: Ramesh, Karthik K., et al.
Publicado: (2023)

Monitoring the effect of belinostat in solid tumors by H4 acetylation
por: MARQUARD, LENA, et al.
Publicado: (2008)

Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma
por: Bodiford, Andrew, et al.
Publicado: (2014)

Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer
por: Chan, Daniel, et al.
Publicado: (2013)

New developments in the treatment of peripheral T-cell lymphoma – role of Belinostat
por: Reimer, Peter
Publicado: (2015)

Antiproliferative effects of TSA, PXD-101 and MS-275 in A2780 and MCF7 cells: Acetylated histone H4 and acetylated tubulin as markers for HDACi potency and selectivity
por: Androutsopoulos, Vasilis P., et al.
Publicado: (2017)

Preclinical efficacy of belinostat in combination with zidovudine in adult T-cell leukemia-lymphoma
por: Toomey, Ngoc, et al.
Publicado: (2015)

Peroxisomes move by hitchhiking on early endosomes using the novel linker protein PxdA
por: Salogiannis, John, et al.
Publicado: (2016)

PxdA interacts with the DipA phosphatase to regulate peroxisome hitchhiking on early endosomes
por: Salogiannis, John, et al.
Publicado: (2021)

Sh3pxd2b Mice Are a Model for Craniofacial Dysmorphology and Otitis Media
por: Yang, Bin, et al.
Publicado: (2011)

Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral t-cell lymphoma
por: Reimer, Peter, et al.
Publicado: (2013)

Belinostat exerts antitumor cytotoxicity through the ubiquitin‐proteasome pathway in lung squamous cell carcinoma
por: Kong, Li R., et al.
Publicado: (2017)

Ritonavir Interacts With Belinostat to Cause Endoplasmic Reticulum Stress and Histone Acetylation in Renal Cancer Cells
por: Isono, Makoto, et al.
Publicado: (2016)

Up-Regulated Expression and Aberrant DNA Methylation of LEP and SH3PXD2A in Pre-Eclampsia
por: Xiang, Yuqian, et al.
Publicado: (2013)

The Role of the Disrupted Podosome Adaptor Protein (SH3PXD2B) in Frank–Ter Haar Syndrome
por: Massadeh, Salam, et al.
Publicado: (2022)

Glucuronidation by UGT1A1 Is the Dominant Pathway of the Metabolic Disposition of Belinostat in Liver Cancer Patients
por: Wang, Ling-Zhi, et al.
Publicado: (2013)

A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction
por: Takebe, Naoko, et al.
Publicado: (2019)

Fission Yeast Pxd1 Promotes Proper DNA Repair by Activating Rad16(XPF) and Inhibiting Dna2
por: Zhang, Jia-Min, et al.
Publicado: (2014)

Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer
por: Dovzhanskiy, Dmitriy I, et al.
Publicado: (2012)

Correction: Glucuronidation by UGT1A1 Is the Dominant Pathway of the Metabolic Disposition of Belinostat in Liver Cancer Patients
por: Wang, Ling-Zhi, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_8e7fqqivubui15if1qjge161gc